Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT: Reversing airway remodelling with tezepelumab in asthma
2022-002891-35Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Change in percentage bronchial wall area (%WA) at B1 and B8 bronchi (generations 3–5). Started Apr 2024; status: active.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-002891-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002891-35.